Long-term Persistent Infection of Macaque Monkeys with the Simian Immunodeficiency Virus
By MUTHIAH D. DANIEL, 1 NORMAN L. LETVIN, 1 PRABHAT K. SEHGAL, x GERHARD HUNSMANN, 2 DIANE K. SCHMIDT, l NORVAL W. KING 1 AND RONALD C. DESROSIERS 1. 1New England Regional Primate Research Center, Harvard Medical School, 1 Pine Hill Drive, Southborough, Massachusetts 01772, U,S.A. and 2 Deutsches Primatenzentrum, Kellnerweg 4, D-3400 G~ttingen, F.R.G. (Accepted 7 August 1987) SUMMARY Juvenile rhesus macaques 6 to 18 months of age were experimentally infected by intravenous inoculation with the simian immunodeficiency virus (SIV), the T celltropic retrovirus of monkeys related to the human acquired immunodeficiency syndrome (AIDS) virus HIV. The SIV used for inoculation was grown either in normal human peripheral blood lymphocytes in the presence of interleukin 2 or in the human tumour cell line HUT-78. Eight of the macaques died 129 to 352 days post-inoculation with a variety of clinical and pathological findings paralleling those of AIDS in humans. However eight other animals became persistently infected ~br prolonged periods; these eight macaques remained alive at 537 and 820 days post-inoculation despite persistent lymphadenopathy and our continued ability to isolate SIV. The ability of these monkeys to survive infection correlated directly with the strength of their antibody response to SIV. Infection was also established in macaques using approximately 100 tissue culture infectious doses of HUT-78-grown SIV. There was no correlation between the dose of virus inoculum and either the strength of the antibody response or clinical outcome. These results demonstrate that SIV infection of macaques can be used not only to study acute AIDS but also to mimic the long-term persistent infection seen in carriers of HIV.
Chimpanzees are the only species that have become infected experimentally upon inoculation with the human immunodeficiency virus (HIV) (Alter et al., 1984; Fultz et al., 1986) . Although this chimpanzee model will undoubtedly be used in a variety of studies relating to AIDS, particularly those involving vaccine development, it has a number of severe limitations. Chimpanzees are an endangered species, expensive and difficult to work with; it is expected that only limited numbers will be available for such studies. Furthermore, chimpanzees have not developed any AIDS-like illness following infection with HIV.
The HIV-related virus of monkeys, simian immunodeficiency virus (SIV), was first isolated from captive rhesus macaques at the New England Regional Primate Research Center . The macaque SIV has growth properties and T4 cell tropism similar to HIV and a characteristic morphogenesis and morphology indistinguishable from HIV and the other lentiviruses Kannagi et al., 1985) . Proteins of SIV are antigenically crossreactive with HIV and the most recent studies indicate approximately 40% overall sequence identity between HIV and SIV (Hirsch et al,, 1986; Chakrabarti et al., 1987) . Despite variation in the cell type used for growing the virus and the dose of the inoculum, we now report that all of our SIV inoculations into macaques resulted in persistent infections; 50 % Short communication . of these persistently infected macaques developed fatal disease. This SIV system thus appears ideally suited to address issues in AIDS research requiring experimental infection in vivo.
In a preliminary study, six juvenile rhesus macaques were inoculated intravenously with the 251 strain of macaque SIV grown in human peripheral blood lymphocytes (PBL) . Four of these six died 127 to 160 days post-inoculation (p.i.) with a wasting syndrome, opportunistic infections, a primary retroviral encephalitis and immunological abnormalities . The fifth animal, Mm74-84, died at 352 days p.i. and the sixth animal, Mm127-83, remains alive at over 820 days p.i. (Table 1 ). Mm74-84 remained persistently infected up until the time of death since SIV was recovered from its peripheral blood mononuclear cells (PBMC) by cocultivation with H9 or HUT-78 cells or with human PBL growing in interleukin 2 (IL-2) at days 19, 53, 144, 256, 271 and 352 p.i . SIV was also recovered from cell-free plasma of Mm74-84 at 53 days p.i. but not at 115 days p.i. Mm 127-83 also remains persistently infected since SIV has been recovered from its PBMC on ten different occasions between 19 and 801 days p.i. Although lymphadenopathy has been noted in Mm127-83, the animal has remained generally healthy.
The post-mortem findings in Mm74-84 included purulent colitis and colonic trichomoniasis, intestinal cryptosporidiosis and multifocal aggregates of lymphoid nodules in the kidneys and bone marrow consistent with a lymphoproliferative disorder as described previously in other macaques (King et al., 1983) . Unlike the other four animals that died following inoculation with human PBL-grown SIV, Mm74-84 had no evidence of a primary retroviral encephalitis.
For additional macaque inoculations, a frozen stock of the second passage of SIV-251 produced in normal human PBL growing in the presence of IL-2 was used to infect HUT-78 cells. Thirty-three days after infection the reverse transcriptase activity measured as described previously reached 140000 c.p.m./ml of cell-free culture supernatant; following filtration, this SIV stock was used to inoculate juvenile macaques. Twelve rhesus macaques 8 to 15 months of age were inoculated intravenously with 1 ml of SIV; four received undiluted virus, four received a 1:50 dilution and four received a 1 : 1000 dilution in RPMI 1640 culture medium (Table 2) .
At 2, 4, 10, 16, 60 and 71 weeks p.i. peripheral blood was drawn from inoculated animals and the mononuclear cells were collected by banding over Ficoll-Hypaque. PBMC were cocultivated with H9 cells or with normal human PBL growing in IL-2 for SIV recovery (Table 3) . Cultured cells were monitored for the appearance of c.p.e, and the appearance of reverse transcriptase activity in the cell-free supernatant. High levels of this activity in the PBL cultures and c.p.e, in H9 cells are unmistakable evidence for the presence of SIV following cocultivation. All macaques were persistently infected since SIV was repeatedly recovered from each animal up to 71 weeks p.i. or until the time of death, even from those animals receiving a 1:1000 dilution of virus (Table 3) . It has been our experience that normal human PBL growing in IL-2 are more sensitive for SIV isolation than the HUT-78 or H9 cell lines.
At 280 days p.i. an air-conditioning malfunction led to extreme overheating in the biocontainment room and resulted in the death of two macaques that had received a 1:1000 dilution of the virus (Table 2) . Three of the remaining ten macaques receiving HUT-78-grown SIV became moribund and were sacrificed 143, 275 and 294 days p.i. (Table 2 ). Each of these three animals developed a transient erythematous maculopapular eruption on the face by 2 Table 3 ). t ELISA at 72 days p.i. (Fig. 1) . ,~ Autopsy findings: thymic atrophy, giant cell pneumonia, granulomatous lymphadenitis and mild focal granulomatous encephalitis.
§ 283-84 and 382-84 died accidentally 280 days p.i. from overheating due to air-conditioning failure. weeks following experimental infection. None were noted to develop clinical evidence of peripheral lymphadenopathy. Two of the monkeys, Mm188-84 and Mm162-84, developed protracted diarrhoea which persisted through the last month of their lives. Mm162-84 lost more than 40~ of its total body weight during the 4½ months following SIV infection.
Quantification of circulating T4 (helper/inducer) and T8 (suppressor/cytotoxic) cells and functional studies of PBL of these animals were performed every 2 weeks for the first 8 weeks p.i. and monthly thereafter. The absolute number of peripheral blood T4 ÷ lymphocytes in Mm392-84 and Mm162-84 fell below the normal level of 1000/mm 3 by 4 weeks p.i. The T4 :T8 ratio in these monkeys, which had been 2.5 : 1 and 1.5 : 1 respectively prior to SIV inoculation, reversed and showed a T8 cell predominance in the peripheral blood until the animals' deaths. While the circulating T4 cell population in Mm188-84 was less than 1000/mm 3 at 4, 6 and 8 weeks p.i., it returned to normal levels and remained normal thereafter.
Results of functional T cell studies were similar in these three animals (Mm162-84, . No abnormalities were noted in peripheral blood T cell proliferative responses to concanavalin A or xenogeneic stimulator cells. However, the helper T lymphocyte-dependent B cell proliferative response of PBL to pokeweed mitogen was decreased to less than 50~ of The pathological findings upon autopsy of these three animals were more variable and less consistent than those observed in the animals inoculated with SIV grown in human PBL. Mm162-84 died of a widely disseminated, unidentified bacterial infection characterized by pulmonary abscesses, purulent pyelonephritis, peritonitis, enteritis, a fibrosing lymphadenitis and a mild granulomatous encephalitis consistent with that caused by SIV. Mm392-84 had a giant cell pneumonia, haemorrhagic and fibrosing giant cell lymphadenitis, membranous glomerulopathy and myelofibrosis. Mm188-84 also had a giant cell pneumonia, pericapsular fibrosis of lymph nodes and extensive amyloidosis of splenic Malpighian corpuscles. No evidence of brain lesions was present in either Mm392-84 or Mm188-84.
Seven macaques that received HUT-78-grown SIV have survived longer than 537 days p.i. despite the persistent infection. Although these in general appear healthy, they have all exhibited a chronic lymphadenopathy, the pathological features of which have recently been described (Chalifoux et al., 1987) . It is, of course, possible that some or all of these animals could still develop severe disease resembling AIDS.
In general, the macaques receiving HUT-78-grown SIV in the second study fared better than those which received PBL-grown virus in the first study. However, it is not entirely clear at this time whether PBL-grown SIV is actually more pathogenic than the HUT-78-grown SIV. Other factors such as heterogeneity in uncloned virus stocks, source of donor PBL for growing the virus, and susceptibility or condition of the animals at the time of inoculation may be important factors contributing to variability in the outcome of these experiments.
One ml of a 1 : 1000 dilution of HUT-78-grown SIV, approximately 100 HUT-78 infectious doses, was clearly sufficient to infect macaques reproducibly. However there was no correlation of the dose of the virus inoculum either with clinical outcome (Table 2) or with the strength of the antibody response ( Fig. 1 b and Table 2 ). In fact, all four macaques that received undiluted, HUT-78-grown SIV are still alive. These results thus indicate that, at least in this experimental setting, long-term persistent infection is just as likely to result from infection with a low dose of virus as with a high dose and that prognosis is no better for those individuals receiving a low dose of virus.
The antibody response in inoculated macaques was monitored by ELISA titration using disrupted whole virus as antigen. When the antibody titre in the six macaques inoculated with PBL-grown virus was measured 88 days p.i. we observed a direct correlation of the strength of the antibody response with the ability to survive infection (Fig. 1 a; Kannagi et al., 1986; Desrosiers et al., 1987) . The four macaques that died 127 to 160 days p.i. had little or no detectable antibodies to SIV; Mm74-84 which lived to 352 days had an intermediate response and Mm127-83, which remains alive despite persistent infection, had the highest antibody titre of the six. When plasma samples taken 72 days p.i. from macaques receiving HUT-78-grown SIV were analysed for SIV antibodies, we observed a similar direct correlation of antibody titre with ability to survive infection ( Fig. 1 b and Table 2 ). In fact, based on the results of antibody titration, we predicted that Mm162-84, Mm188-84 and Mm392-84 would be the first macaques to die in this study well before significant clinical signs were evident; this was indeed the case (Table 2) . Plasma samples taken from the seven surviving macaques at 526 days p.i. contained antibody titres of 1:81000 and higher against SIV.
The presence of neutralizing antibodies in these macaques was determined using a slightly modified version of a newly developed procedure for HIV neutralization based on the extreme sensitivity of MT-4 cells to HIV-induced c.p.e. (Harada et al., 1986; Wendler et al., 1987) . When 50 ~tl of frozen SIV stock diluted 1:20 to 1:1000 was added to MT-4 cells growing in 96-well plates, little or no [3H]thymidine was incorporated by the infected cells 11 days later due to the c.p.e, of the virus (i.e. background levels of 100 to 500 c.p.m.); uninfected cells incorporated 50 000 to 100 000 c.p.m, in this assay. These measurements thus allowed accurate quantification of MT-4 tissue culture infectious doses (TCIDs0) (Fig. 2a) . The S1V frozen at -70 °C in multiple vials for these studies was calculated to contain approximately 1.5 x 105 TCIDso per ml (Fig.  2 a) . For neutralization tests, 25 ~tl of a 1:400 dilution of stock virus (i.e. about 10 TCIDs0) was mixed with 25 ~tl of diluted test serum or plasma, incubated and then added to MT-4 cells. Neutralizing sera were those that increased [3H]thymidine incorporation from background levels to 25000 to 100000 c.p.m, when mixed with the SIV. Sera and plasma from various antibody-negative macaques did not show any neutralizing activity, whereas plasma from all experimentally infected macaques exhibiting high ELISA titres and from most exhibiting lower ELISA titres had neutralizing antibodies (Fig. 2b and Table 4 ). Plasma samples with high ELISA titres also gave high neutralization titres. * Neutralization titre is taken as the last dilution of plasma that yielded at least 50 ~ of maximal [3H]thymidine incorporation in the assay described in the legend to Fig. 2 .
Thus, the clinical outcome in these experimental infections correlated directly with antibody response. The long-term survivors of SIV infection consistently had much higher antibody titres to SIV when measured by ELISA and these antibodies had neutralizing activity. This does not necessarily mean, however, that it is the antibodies themselves that had a clinically protective effect since other factors such as cell-mediated immunity could also possibly correlate with anti-SIV antibody levels. The disease response also correlated with other findings indicative of a damaged immune system, e.g. numbers of T4 ÷ lymphocytes and total plasma IgG (Kannagi et al., 1986) . Protective immunity in such infections can only mean protection from rapid death since all long-term survivors have remained persistently infected. It is not yet known which arms of the immune system are most important for this protection against disease development nor which need to be most stimulated for a vaccine to be effective. Low titres of antibody to HIV in seropositive humans have recently been associated with increased risk for subsequent development of AIDS (Polk et al., 1987) and have been correlated with more advanced disease (Ho et al., 1987) . Moreover, a limited longitudinal study of human HIV carriers suggested that the development of a strong neutralizing antibody response protects against the progression of AIDS (Wendler et al., 1987) .
There are many good reasons to continue development of the SIV-macaque system for studying AIDS. The virus is similar to the human AIDS virus in morphology, genetic sequence, cell tropism and growth properties and we have now shown that it consistently produces persistent infection in the common rhesus monkey after experimental inoculation. Many of these monkeys die with clinical and pathological findings with remarkable parallels to AIDS in man. The SIV-macaque system will be best utilized to address issues requiring infection in vivo, for example to study disease pathogenesis and for vaccine development. Since many of the critical issues regarding HIV and AIDS revolve around viral persistence, the SIV-macaque system can also be used to study the mechanisms by which this persistent infection is achieved and maintained.
